StocksMedium•6 October 2026•
1 min read
Enliven Therapeutics Reaches FDA Agreement on Phase 3 Trial for Leukemia Treatment
Key Facts
1Enliven Therapeutics reached an agreement with the FDA on the design of a Phase 3 trial for its leukemia treatment, Relcobatinib.
Enliven Therapeutics reached an agreement with the FDA on the design of a Phase 3 trial for its leukemia treatment, Relcobatinib. Reuters reported that the alignment covers the clinical testing framework for the drug, which targets Chronic Myeloid Leukemia (CML).
The alignment on the trial design serves as a critical regulatory milestone, enabling the company to proceed with late-stage clinical testing for its lead drug candidate. This progress occurred alongside broader global economic shifts, including various inflation and industrial production data released on September 30, 2026.